$82 billion pharma giant Bristol-Myers Squibb just suffered a major setback in its hunt for a lung cancer treatment, but the drugmaker isn't backing away from its controversial strategy

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 51%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Bristol-Myers has been trying to prove that its cancer drugs work to treat a common type of lung cancer. But the company just pulled its US application.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Why don’t they steal the vaccine from Cube?

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Bristol-Myers shares fall after it withdraws FDA application for combo lung cancer treatmentThe New York-based pharmaceutical giant said it pulled its applications for a combination of its immunotherapy drugs Opdivo and Yervoy after recent discussions with the FDA. Cost of Opdivo +Yervoy combo is $256K/yr in melanoma (approved in indication). Thus, additional pressure on efficacy:safety to justify a very high cost in lung cancer - Bristol-Myers shares fall after it withdraws FDA application for combo lung cancer tx
Source: CNBC - 🏆 12. / 72 Read more »

Bristol-Myers shares fall after it withdraws FDA application for combo lung cancer treatmentThe New York-based pharmaceutical giant said it pulled its applications for a combination of its immunotherapy drugs Opdivo and Yervoy after recent discussions with the FDA. Cost of Opdivo +Yervoy combo is $256K/yr in melanoma (approved in indication). Thus, additional pressure on efficacy:safety to justify a very high cost in lung cancer - Bristol-Myers shares fall after it withdraws FDA application for combo lung cancer tx
Source: CNBC - 🏆 12. / 72 Read more »

A top Novartis executive says the $225 billion drug giant is planning for a 'doomsday scenario' in cancer treatmentPharma giant Novartis is developing drugs that could prevent cancer before patients get it. One big question: how will we pay for them?
Source: BusinessInsider - 🏆 729. / 51 Read more »

Promising new drug for aggressive stage IV breast cancer encounters setbackPromising new drug for aggressive stage IV breast cancer delayed by FDA. It must be effective for the FDA to deny it... There;s a reason we have a government. Are the SES bureaucrats holding our for more consulting money gratuities, or do the political appointees want donations?
Source: ABC - 🏆 471. / 51 Read more »